The survival prediction of advanced colorectal cancer received neoadjuvant therapy—a study of SEER database

• Published in: World journal of surgical oncology Vol. 22; no. 1; pp. 175 - 12
• Main Authors: Han, Zhuo, Yang, Haicheng, Qiao, Qing, Wu, Tao, He, Xianli, Wang, Nan
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 01.07.2024; BioMed Central; BMC
• Subjects: Adult; Aged; Care and treatment; Colorectal cancer; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Colorectal Neoplasms - therapy; CRC; Female; Follow-Up Studies; Humans; LODDS; Lymphatic Metastasis; Male; Methods; Middle Aged; Neoadjuvant therapy; Neoadjuvant Therapy - methods; Neoadjuvant Therapy - mortality; Neoadjuvant Therapy - statistics & numerical data; Neoplasm Staging; Nomograms; Nomography (Mathematics); Patient outcomes; Prognosis; Retrospective Studies; SEER database; SEER Program - statistics & numerical data; Survival; Survival Rate; China; Neoadjuvant therapy; SEER database; LODDS; CRC; Survival
• ISSN: 1477-7819; 1477-7819
• DOI: 10.1186/s12957-024-03458-7

The aim of study was to screen factors associated with the overall survival of colorectal cancer patients with lymph nodes metastasis who received neoadjuvant therapy and construct a nomogram model. All enrolled subjects of the SEER database were randomly assigned to the training and testing group in a ratio of 3:2. The patients of Tangdu Hospital were seemed as validation group. Univariate cox regression analysis, lasso regression and random forest survival were used to screen variables related to the survival of advanced CRC patients received neoadjuvant therapy in the training group. Area under curves were adopted to evaluate the 1,3,5-year prediction value of the optimal model in three cohorts. Calibration curves were drawn to observe the prediction accuracy of the nomogram model. Decision curve analysis was used to assess the potential clinical value of the nomogram model. A total of 1833 subjects were enrolled in this study. After random allocation, 1055 cases of the SEER database served as the training group, 704 cases as the testing group and 74 patients from our center as the external validation group. Variables were screened by univariate cox regression used to construct a nomogram survival prediction model, including M, age, chemotherapy, CEA, perineural invasion, tumor size, LODDS, liver metastasis and radiation. The AUCs of the model for predicting 1-year OS in the training group, testing and validation group were 0.765 (0.703,0.827), 0.772 (0.697,0.847) and 0.742 (0.601,0.883), predicting 3-year OS were 0.761 (0.725,0.780), 0.742 (0.699,0.785), 0.733 (0.560,0.905) and 5-year OS were 0.742 (0.711,0.773), 0.746 (0.709,0.783), 0.838 (0.670,0.980), respectively. The calibration curves showed the difference between prediction probability of the model and the actual survival was not significant in three cohorts and the decision curve analysis revealed the practice clinical application value. And the prediction value of model was better for young CRC than older CRC patients. A nomogram model including LODDS for the prognosis of advanced CRC received neoadjuvant therapy was constructed and verified based on the SEER database and single center practice. The accuracy and potential clinical application value of the model performed well, and the model had better predictive value for EOCRC than LOCRC.